As our Numerof 2023 Global Pharma Outlook infographic illustrates, this year’s story for pharmaceutical manufacturers will be about continuing to adapt to pressures on price, especially mandated government negotiation, and demands for value while dealing with the long-term effects of the pandemic.
As our Numerof 2023 Global Medical Device Outlook infographic illustrates, this year’s story for medical device manufacturers will be about reconciling overhead inflation with market pressure on pricing, responding to demands for a data-based value narrative, and adjusting the commercialization process to an emerging post-pandemic reality.
While the pandemic has continued to accelerate changes to the pharma business model, other factors – healthcare consolidation, the upcoming election, bipartisan support for direct negotiation – are impacting all aspects of development, commercialization, and market access. In response to these market dynamics, manufacturers have been adapting their commercial approaches.…
Among the many trends accelerated by the pandemic was the overhaul of pharma’s commercial model. It was tacitly understood to be ripe for change – the cost was increasingly conspicuous, and the results increasingly suspect. The prior model had grown out of step with field realities. Employed physicians had less…
